Your fact-checks will appear here
The use of immune checkpoint inhibitors in cancer treatment and potential liver injury
A small but consistent body of case reports links self‑administration of veterinary fenbendazole by cancer patients to clinically significant drug‑induced liver injury (DILI), including severe hepatoc...
Microsatellite-stable (MSS) colorectal cancer has largely been refractory to single‑agent immune checkpoint inhibitors, so current clinical research is focused on rational combinations—checkpoint dual...
Clinical testing of ivermectin in cancer patients remains nascent: searches of the clinical literature and trial registries identify essentially one active early-phase trial combining ivermectin with ...
Ivermectin has generated a steady body of preclinical literature showing antiproliferative, pro‑apoptotic and immunomodulatory effects across multiple cancer cell lines and animal models, but human cl...
As of 2025, ClinicalTrials.gov shows a single registered interventional study testing ivermectin for cancer: a Phase I/II trial (NCT05318469) combining oral ivermectin with an immune checkpoint inhibi...